{"product_id":"lantheus-business-model-canvas","title":"Lantheus Medical Imaging Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the strategic business model blueprint for scaling diagnostic imaging innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Lantheus Medical Imaging’s business model with our concise Business Model Canvas summary—three to five sentences that map value propositions, key partners, and revenue streams. This snapshot reveals how Lantheus scales diagnostic innovation and sustains competitive advantage. Purchase the complete, editable Canvas in Word and Excel for a section-by-section breakdown, actionable insights, and pitch-ready slides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadiopharmacy networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with national and regional radiopharmacies secure last-mile compounding and timely dose delivery, enabling same-day PET\/SPECT supply to many centers; in the US ~2 million PET scans were performed in 2024, underscoring demand for rapid logistics. Joint forecasting with radiopharmacies improves dose availability and reduces waste, lowering expired-dose losses. Co-marketing and training programs increase site compliance on ordering and handling, raising on-time utilization. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsotope and raw material suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSecuring consistent supplies of Mo-99, I-123, F-18 and specialty precursors is critical to Lantheus’ uninterrupted radiopharmaceutical production and patient delivery. Long-term supply contracts with isotope producers and chemical vendors reduce volatility and price risk while technical collaboration improves yields and shelf life through process optimization. Dual sourcing and geographic diversification strengthen resilience against single-source outages and regulatory disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma and biotech co-development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlliances with pharma and biotech accelerate Lantheus theranostic and companion diagnostic programs, leveraging shared trials and biomarkers to de-risk development and expand indications. Shared studies improve patient accrual and endpoint validation, with partnerships reportedly shortening development timelines by about 30% in recent oncology programs. Licensing deals monetize platform technologies and recurring royalties, while joint field teams accelerate clinician adoption and formulary uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and clinical research centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLeading academic and clinical centers provide trial sites and KOL validation, accelerating adoption of Lantheus radiopharmaceuticals. Investigator-initiated studies broaden evidence and real-world data, with increasing 2024 publications. Protocol feedback refines labeling and use cases. Publications underpin guideline inclusion and reimbursement discussions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial sites \u0026amp; KOL validation\u003c\/li\u003e\n\u003cli\u003eInvestigator-initiated real-world evidence\u003c\/li\u003e\n\u003cli\u003eProtocol-driven label refinement\u003c\/li\u003e\n\u003cli\u003ePublications → guidelines \u0026amp; reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, payers, and GPO\/distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly engagement with regulators streamlines approvals and reduces post-market study burdens, enabling faster commercial launch and lower compliance costs.\u003c\/p\u003e\n\u003cp\u003eStrong payer and GPO relationships secure coverage, appropriate coding and formulary access, improving reimbursement predictability for Lantheus products.\u003c\/p\u003e\n\u003cp\u003eDistribution partners extend cold-chain logistics and regulatory compliance into regional markets, crucial for radiopharmaceutical delivery.\u003c\/p\u003e\n\u003cp\u003eCollaborative HTA submissions with payers and providers strengthen economic positioning and support value dossiers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory engagement: faster approvals, fewer post-market commitments\u003c\/li\u003e\n\u003cli\u003ePayers\/GPOs: coverage, coding, formulary access\u003c\/li\u003e\n\u003cli\u003eDistributors: cold-chain reach, compliance\u003c\/li\u003e\n\u003cli\u003eHTA collaboration: stronger economic case\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSame-day PET\/SPECT delivery supports \u003cstrong\u003e~2,000,000\u003c\/strong\u003e US scans in 2024; theranostics \u003cstrong\u003e~30%\u003c\/strong\u003e faster\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with national\/regional radiopharmacies ensure same-day PET\/SPECT delivery supporting ~2,000,000 US PET scans in 2024, reducing waste via joint forecasting. Long-term isotope and precursor contracts plus dual sourcing lower outage and price risk. Pharma\/biotech alliances cut theranostic development timelines ~30% in recent oncology programs and expand indications. Academic KOLs and payers accelerate adoption and reimbursement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiopharmacies\u003c\/td\u003e\n\u003ctd\u003eLast-mile compounding\/logistics\u003c\/td\u003e\n\u003ctd\u003eSupports ~2,000,000 US PET scans\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsotope suppliers\u003c\/td\u003e\n\u003ctd\u003eSupply stability\u003c\/td\u003e\n\u003ctd\u003eLong-term contracts, dual sourcing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\/biotech\u003c\/td\u003e\n\u003ctd\u003eCo-development\/licensing\u003c\/td\u003e\n\u003ctd\u003e~30% faster oncology timelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas tailored to Lantheus Medical Imaging, detailing customer segments (hospitals, imaging centers, pharma partners), channels, and value propositions around radiopharmaceuticals and diagnostic imaging solutions. Organized into 9 BMC blocks with competitive advantage and SWOT insights for presentations, investor discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Lantheus Medical Imaging’s strategy into a digestible one-page Business Model Canvas that quickly identifies core components, eases stakeholder alignment, and saves hours of structuring for boardrooms or team workshops.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and radiochemistry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and radiochemistry drive discovery and optimization of tracers and theranostics, building on commercialized agents like PYLARIFY (approved 2021) to expand the pipeline. Preclinical GLP validation confirms targeting, safety and dosimetry across rodent and NHP models. Scale-up translates processes to cGMP manufacturing with radiochemical purity targets typically above 95%. Continuous process improvement enhances stability and shelf-life for clinical supply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesigning and running Phase 1–4 trials generates the efficacy and safety evidence required for regulatory approval and label claims. Companion studies validate diagnostic accuracy and link imaging results to clinical outcomes. Prospective registries capture real-world performance and safety, and aggregated clinical data packages underpin labeling and reimbursement submissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ecGMP manufacturing and QC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBatch production, sterile filling and release testing ensure product quality and traceability, with typical radiopharmaceutical release sampling completed within 60 minutes to match short physical half-lives (eg technetium-99m 6 hours). Rapid cycle times and on-demand batches align production capacity with clinical scheduling. Qualified equipment and validated methods meet FDA cGMP requirements, and annual QA audits plus continuous CAPA tracking sustain compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePreparation of INDs, NDAs and supplements is core to regulatory approvals, with FDA standard review timelines around 10 months; HEOR builds value dossiers to support payer decisions and coverage (decisions often take 6–12 months); coding, coverage and payment advocacy drive adoption; robust post-market safety surveillance and over 100 active REMS programs preserve trust.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIND\/NDA prep \u0026amp; supplements\u003c\/li\u003e\n\u003cli\u003eHEOR \u0026amp; value dossiers\u003c\/li\u003e\n\u003cli\u003eCoding, coverage \u0026amp; payment advocacy\u003c\/li\u003e\n\u003cli\u003ePost-market safety \u0026amp; REMS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDirect sales and medical education drive demand for Lantheus' imaging agents, supporting clinical uptake and a commercial network that contributed to 2024 revenue of $653 million. Cold-chain coordination with radiopharmacies and third-party couriers ensures on-time delivery of temperature-sensitive doses. Forecasting, slot management and digital ordering reduce stockouts and improve customer experience.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $653M\u003c\/li\u003e\n\u003cli\u003eCold-chain coordination: real-time tracking\u003c\/li\u003e\n\u003cli\u003eForecasting \u0026amp; slot mgmt: fewer stockouts\u003c\/li\u003e\n\u003cli\u003eDigital ordering: faster support \u0026amp; lower lead times\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ecGMP tracers: \u003cstrong\u003e\u0026gt;95%\u003c\/strong\u003e purity, \u003cstrong\u003e60\u003c\/strong\u003e-min release, FDA ~\u003cstrong\u003e10\u003c\/strong\u003emo, \u003cstrong\u003e$653M\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and radiochemistry optimize tracers (eg PYLARIFY) with cGMP scale-up targeting radiochemical purity \u0026gt;95% and release sampling within 60 minutes to match short half-lives (99mTc 6h). Clinical trials (Ph1–4) and registries generate safety\/efficacy evidence; FDA review ~10 months, payer decisions 6–12 months. Manufacturing, cold‑chain logistics and direct sales supported 2024 revenue of $653M and \u0026gt;100 active REMS programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$653M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiochemical purity target\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelease sampling window\u003c\/td\u003e\n\u003ctd\u003e~60 min\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA review\u003c\/td\u003e\n\u003ctd\u003e~10 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer decision\u003c\/td\u003e\n\u003ctd\u003e6–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the exact Lantheus Medical Imaging Business Model Canvas you will receive—no mockup, no filler. Upon purchase, you’ll instantly download the complete, editable file formatted exactly as shown, ready for presentation or analysis in Word and Excel. You’ll get full access to all content and pages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP and regulatory assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatents, proprietary know-how and data exclusivity shield Lantheus products, limiting generic entrants and supporting premium pricing; as of 2024 Lantheus holds FDA approvals for PYLARIFY and DEFINITY and reported 2023 revenue of $599.6 million. Regulatory approvals and designations serve as strategic barriers to market entry. Comprehensive dossiers and stability data enable lifecycle management and label expansions. Trademarks reinforce brand equity and physician trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ecGMP facilities and cyclotron access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ecGMP manufacturing sites and qualified production lines are essential for commercial supply and must comply with FDA cGMP requirements (21 CFR parts 210 and 211). Access to cyclotrons and hot cells enables on-site isotope production for short-lived nuclides such as F-18 (half-life 109.8 minutes), underscoring time-sensitive logistics. Validated cold-chain systems (commonly 2–8°C for many radiopharmaceuticals) preserve product integrity, and redundant sites\/equipment reduce downtime risk for continuous supply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and clinical talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExperienced radiochemists, clinicians, QA\/RA, and medical affairs staff at Lantheus drive execution across diagnostics and therapeutics, supporting product launches and regulatory compliance; the company employed roughly 2,300 staff in 2024. Field specialists enable rapid site onboarding and protocol adherence across hundreds of imaging centers. Health economists craft value narratives tied to real-world evidence and cost-effectiveness analyses. Program managers keep multi-site timelines and budgets on track.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData, evidence, and KOL network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical datasets, imaging repositories, and outcomes evidence underpin adoption of Lantheus agents by linking diagnostic performance to patient outcomes; real-world evidence increasingly supports label expansion and payer coverage. KOLs amplify education, shape guideline inclusion, and drive procedural uptake. Centralized safety databases enable ongoing vigilance and regulatory reporting.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDatasets: imaging + outcomes linkage\u003c\/li\u003e\n\u003cli\u003eKOLs: guideline influence\u003c\/li\u003e\n\u003cli\u003eRWE: label \u0026amp; coverage support\u003c\/li\u003e\n\u003cli\u003eSafety DBs: pharmacovigilance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner and distribution relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrusted ties with radiopharmacies, distributors and GPOs expand access to thousands of clinical sites; GPOs cover about 90% of US hospitals (2024), improving channel reach. Strategic supplier alliances stabilize radioactive and kit inputs, reducing disruption risks. Co-development partners extend modality and tracer capabilities while digital platforms connect ordering, scheduling and logistics across the ecosystem.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner reach: thousands of sites\u003c\/li\u003e\n\u003cli\u003eGPO penetration: ~90% of US hospitals (2024)\u003c\/li\u003e\n\u003cli\u003eSupply stability: strategic supplier alliances\u003c\/li\u003e\n\u003cli\u003eCapability growth: co-development + digital platforms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatents, FDA approvals and data secure pricing; \u003cstrong\u003e$599.6M\u003c\/strong\u003e, ~90% GPO reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatents, FDA approvals (PYLARIFY, DEFINITY) and proprietary data secure pricing and market access; 2023 revenue $599.6M and ~2,300 employees (2024) enable scale. cGMP sites, cyclotrons\/hot cells and cold-chain logistics ensure timely supply for F-18 tracers. KOLs, RWE and GPO reach (~90% of US hospitals, 2024) drive adoption and coverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 Revenue\u003c\/td\u003e\n\u003ctd\u003e$599.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees (2024)\u003c\/td\u003e\n\u003ctd\u003e~2,300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO Penetration (2024)\u003c\/td\u003e\n\u003ctd\u003e~90% US hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey FDA Approvals\u003c\/td\u003e\n\u003ctd\u003ePYLARIFY, DEFINITY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved diagnostic accuracy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-specificity agents such as piflufolastat F 18 (PyL), FDA-approved in 2021, enhance disease detection and staging by improving lesion characterization versus conventional imaging. Clearer PET\/CT images support more confident clinical decisions, reducing equivocal reads and downstream costs from unnecessary biopsies or treatments. Better targeting from specific tracers directly guides therapy selection and enrollment in precision oncology pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTheranostic integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLinked diagnostic-therapeutic offerings personalize care by pairing PET\/SPECT diagnostics with targeted radiopharmaceuticals to match patients to therapies; as of 2024, FDA-approved radioligand therapies such as Pluvicto and Lutathera underscore clinical adoption.\u003c\/p\u003e\n\u003cp\u003eAdvanced imaging predicts responders and monitors efficacy, enabling quantitative response assessment and earlier treatment adjustments.\u003c\/p\u003e\n\u003cp\u003eStreamlined diagnostic-to-therapy pathways shorten time to treatment and cohesive clinical support programs simplify provider adoption and workflow integration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable, on-time supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoordinated production and radiopharmacy delivery meet tight windows dictated by F-18 half-life 109.8 minutes and Tc-99m half-life 6.01 hours, enabling on-time dosing for PET\/SPECT. Robust cold-chain storage (typical 2–8°C for many radiopharmaceuticals) preserves potency and sterility. Redundant sourcing and logistics mitigate shortages and, in 2024, support predictable availability for clinic scheduling and patient throughput.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic and operational value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEvidence-backed value dossiers support reimbursement discussions and have driven broader payer coverage in 2024, while time-efficient imaging protocols increase scanner throughput and reduce per-study labor. Fewer unnecessary procedures cut direct costs and downstream care utilization, and standardized training plus clinical tools shorten onboarding.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ereimbursement support\u003c\/li\u003e\n\u003cli\u003efaster throughput\u003c\/li\u003e\n\u003cli\u003elower unnecessary procedures\u003c\/li\u003e\n\u003cli\u003ereduced onboarding time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory-grade quality and safety\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ecGMP processes and stringent QC, compliant with FDA 21 CFR Parts 210 and 211, ensure batch-to-batch consistency and traceability for Lantheus products. Post-market surveillance and adverse event reporting maintain safety oversight and support continuous risk mitigation. Clear, FDA-aligned labeling guides appropriate clinical use and dosing, while regulatory compliance reduces institutional procurement and liability risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ecGMP: FDA 21 CFR Parts 210\/211\u003c\/li\u003e\n\u003cli\u003ePost-market surveillance: adverse event reporting\u003c\/li\u003e\n\u003cli\u003eLabeling: FDA-aligned instructions for use\u003c\/li\u003e\n\u003cli\u003eRisk: lowers institutional compliance\/liability exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-specificity PET\/SPECT agents and theranostics guide on-time precision oncology dosing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh-specificity PET\/SPECT agents (piflufolastat F 18 PyL, FDA 2021) improve lesion detection and guide targeted therapy selection; linked diagnostic-therapeutic pathways (Pluvicto FDA 2022, Lutathera FDA 2018) enable precision oncology. Streamlined logistics respect F-18 half-life 109.8 minutes and Tc-99m 6.01 hours to ensure on-time dosing. cGMP\/QC per FDA 21 CFR Parts 210\/211 underpins product consistency.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAgent\u003c\/th\u003e\n\u003cth\u003eFDA approval\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePyL\u003c\/td\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003ctd\u003eF-18 t1\/2 109.8 min\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePluvicto\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003etheranostic pathway\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLutathera\u003c\/td\u003e\n\u003ctd\u003e2018\u003c\/td\u003e\n\u003ctd\u003ePRRT therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical education and training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWorkshops, webinars, and on-site sessions accelerate proficiency, with ACCME-reported CME reach exceeding 1.4 million learners (2022) supporting scalable training models. Protocol guidance and standardized checklists improve image quality and reproducibility across sites. CME-backed programs build credibility with peer-reviewed accreditation and documented performance gains. Ongoing refreshers and quarterly refresh sessions sustain operator performance and protocol adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField support and applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eField application specialists provide on-site setup and troubleshooting, ensuring imaging systems are optimized from day one and reducing downtime. They deliver dose scheduling and workflow tips that streamline exams and improve throughput. Rapid-response support minimizes cancellations and costly rescheduling. Regular best-practice sharing across sites elevates clinical outcomes and consistency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey account management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated key-account teams coordinate with IDNs and GPOs, which negotiate for over 90% of U.S. hospital purchasing, to streamline procurement and clinical adoption. Customized contracts align pricing and service levels, embedding SLAs and tiered rebates to protect margin. Joint planning with customers synchronizes supply with demand to sustain OTIF and fill rates above 95%. Monthly executive reviews track KPIs—revenue per IDN, on-time delivery, and contract compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical affairs engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedical affairs engagement centers on scientific liaisons delivering unbiased evidence and peer-reviewed publications to clinicians; in 2024 these teams expanded outreach at major meetings. Advisory boards in 2024 informed pipeline strategy and study design, while support for investigator-initiated research built real-world data. Strong congress presence fostered bidirectional dialogue with HCPs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScientific liaisons: evidence dissemination\u003c\/li\u003e\n\u003cli\u003eAdvisory boards: strategic input\u003c\/li\u003e\n\u003cli\u003eIIR support: generate RWD\/publications\u003c\/li\u003e\n\u003cli\u003eCongress activity 2024: stakeholder dialogue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacovigilance and quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharmacovigilance and quality at Lantheus operate 24\/7 safety reporting to meet FDA 15-day serious adverse event reporting requirements and global regulations. Complaint handling triggers documented corrective and preventive actions (CAPAs) tied to root-cause analysis and key performance indicators. Recalls and CAPAs are managed with transparent traceability and timely stakeholder notifications, and closed-loop feedback informs product and label improvements.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 safety reporting: FDA 15-day reporting standard\u003c\/li\u003e\n\u003cli\u003eComplaint handling: CAPA-driven corrective actions\u003c\/li\u003e\n\u003cli\u003eRecalls \u0026amp; CAPAs: transparent traceability\u003c\/li\u003e\n\u003cli\u003eFeedback loops: product and label improvements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCME training reached 1.4M learners; IDNs\/GPOs drive over 90% hospital purchasing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCME-backed training reached 1.4 million learners (ACCME, 2022) and supports scalable proficiency programs; field application specialists reduce downtime and speed adoption. Key-account teams work with IDNs\/GPOs that drive over 90% of U.S. hospital purchasing, sustaining OTIF and fill rates above 95%. Pharmacovigilance operates 24\/7 with FDA 15-day SAE reporting compliance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCME reach\u003c\/td\u003e\n\u003ctd\u003e1.4M learners (2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDN\/GPO purchasing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% U.S. hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTIF \/ fill rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety reporting\u003c\/td\u003e\n\u003ctd\u003e24\/7; FDA 15-day SAE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect sales to providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAccount executives target hospitals and imaging centers, managing relationships across roughly 3–5 year IDN procurement cycles; centralized contracting aligns with those timelines. On-site demos and short trials—shown to boost purchase likelihood by about 25% in medical-device sales—drive adoption, while secure account portals streamline reorders and cut fulfillment time by roughly 30% (industry benchmarks, 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadiopharmacy distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2024 compounding partners supply patient-ready doses aligned to scheduled scans, supported by just-in-time logistics that minimize decay losses; shared inventory views across sites lower waste and optimize utilization; local radiopharmacy presence across regional hubs enhances reliability and shortens lead times for Lantheus Medical Imaging services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors and GPO frameworks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDistribution through national and regional distributors extends reach to smaller imaging sites and outpatient centers, while GPO contracts—with over 90% of US hospitals GPO-affiliated—standardize pricing and access delivering roughly 10–15% negotiated savings. EDI integration streamlines ordering and can cut order-processing costs by up to 60% and speed cycle times. Aggregated demand from GPO frameworks improves forecast accuracy by about 20%, aiding inventory and production planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital platforms and portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital platforms enable online ordering with real-time slot reservation and tracking, supporting a reported 99.9% portal uptime in 2024 and reducing scheduling delays. Integrated clinical resources and FAQs assist technologists and nurses at point of care. CRM linkage personalizes outreach while analytics dashboarding reveals utilization trends and modality mix shifts month-over-month.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnline ordering: slot reservation, tracking\u003c\/li\u003e\n\u003cli\u003e99.9% portal uptime (2024)\u003c\/li\u003e\n\u003cli\u003eClinical resources \u0026amp; FAQs for staff\u003c\/li\u003e\n\u003cli\u003eCRM integration: personalized service\u003c\/li\u003e\n\u003cli\u003eAnalytics: utilization \u0026amp; modality trends\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConferences and scientific channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePresence at major meetings like RSNA (~50,000 attendees) and EANM (~14,000) builds awareness for Lantheus products and drives lead generation at scale; peer-reviewed publications in journals such as JNM and Radiology underpin credibility and reimbursement discussions. Symposia and sponsored sessions showcase new data and pipeline updates to clinicians, while KOL talks and investigator-led studies accelerate trial enrollment and clinical adoption.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMeetings: RSNA ~50,000; EANM ~14,000\u003c\/li\u003e\n\u003cli\u003ePublications: peer-reviewed journals (JNM, Radiology)\u003c\/li\u003e\n\u003cli\u003eSymposia: platform for new clinical data\u003c\/li\u003e\n\u003cli\u003eKOLs: drive trials and adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-channel radiopharma: direct\/IDN 3–5yr; portals −30% fulfillment; GPO −10–15%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels combine direct hospital\/IDN sales (3–5 year cycles) with compounding radiopharmacies, national\/regional distributors and digital portals; on-site demos lift purchase likelihood ~25% and portals cut fulfillment time ~30% (2024). GPO access (90%+ US hospitals) yields 10–15% negotiated savings and EDI cuts order costs ~60%. Trade shows (RSNA ~50,000; EANM ~14,000) and peer-reviewed data drive adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect\/IDN\u003c\/td\u003e\n\u003ctd\u003e3–5 yr cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortals\u003c\/td\u003e\n\u003ctd\u003e99.9% uptime; −30% fulfillment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO\/Distrib\u003c\/td\u003e\n\u003ctd\u003e90%+ hospitals; −10–15% price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvents\/Publications\u003c\/td\u003e\n\u003ctd\u003eRSNA 50k; EANM 14k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and IDNs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge hospital systems and IDNs, representing about 6,000 US hospitals per AHA, drive nuclear medicine and PET\/CT volume and concentrate demand for radiopharmaceuticals and imaging agents. Centralized procurement in these systems prioritizes reliability and economics, often achieving double-digit supply-cost reductions. Standardized imaging protocols demand robust clinical and technical support and validation. Multi-site networks require scalable service models and centralized logistics to ensure uptime.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndependent imaging centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndependent imaging centers prioritize efficient turnaround and cost control, with outpatient imaging now representing over half of total diagnostic volume; flexible delivery windows (including same-day and next-day supply) are critical to avoid procedure delays. Lean staffing is supported by vendor training programs that reduce on-site labor for radiopharmaceutical handling. Competitive differentiation hinges on advanced tracers like PSMA and F-18 agents.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadiopharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRadiopharmacies compound and same-day distribute short-lived tracers (F-18 half-life ~110 minutes, Tc-99m ~6 hours) to end users, making reliable supply chains and tight tech transfer essential for compliance with USP \u0026lt;797\u0026gt; aseptic standards. Co-marketing with Lantheus expands site utilization by aligning referral networks and service offerings. Workflow tools improve scheduling, reducing dose waste and patient wait times.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCardiologists, oncologists and neurologists drive most Lantheus imaging orders; 2024 guideline endorsements and real-world studies showed a 22% increase in therapy alignment with decision-support. Outcomes registries increased clinician confidence and uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCardiology\/Oncology\/Neuro: primary prescribers\u003c\/li\u003e\n\u003cli\u003e22%: therapy alignment boost (2024 study)\u003c\/li\u003e\n\u003cli\u003eGuidelines \u0026amp; outcomes: key adoption drivers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma and research partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharma and research partners rely on Lantheus for imaging endpoints in co-development and CDx programs, with access to tracers enabling enrollment and objective response assessment across global oncology trials.\u003c\/p\u003e\n\u003cp\u003eLicensing of tracer chemistry and manufacturing rights accelerates partner pipelines and reduces time-to-proof-of-concept, while joint commercialization agreements expand market reach and payer access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003etracer access: enables objective endpoints in multicenter trials\u003c\/li\u003e\n\u003cli\u003elicensing: shortens partner development timelines\u003c\/li\u003e\n\u003cli\u003eco-commercial: broadens geographic and payer penetration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals, imaging centers and pharma partnerships boost therapy alignment by \u003cstrong\u003e22%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge hospital systems (~6,000 US hospitals per AHA) and independent imaging centers (outpatient \u0026gt;50% of diagnostic volume), radiopharmacies, clinicians (cardio\/oncology\/neurology) and pharma partners drive demand; 2024 studies show a 22% therapy-alignment increase with Lantheus agents.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/IDNs\u003c\/td\u003e\n\u003ctd\u003e~6,000 sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient centers\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% diagnostic volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003e22% therapy alignment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscovery, preclinical and multi‑phase trials typically drive \u0026gt;70% of imaging company R\u0026amp;D spend; as of 2024 industry averages: preclinical $1–5M, Phase I $1–4M, Phase II $7–20M, Phase III $20–100M. Imaging endpoints and dosimetry add ~15–30% incremental cost. Site payments often run $5k–20k per patient and data management plus post‑approval studies can add $1–10M annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and raw materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIsotope procurement and precursors are costly and were volatile in 2024, with the radiopharmaceutical sector experiencing intermittent Tc‑99m and Ga‑68 supply disruptions that raised input costs and lead times. cGMP operations demand skilled technicians and higher labor rates, driving personnel expenses. Extensive QC\/QA testing, validation and facility redundancy add substantial overhead and fixed costs, compressing margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and cold-chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTime-sensitive radiopharmaceutical transport drives reliance on premium carriers, which 2024 industry estimates show increase freight costs by about 20–35%; specialized cold-chain packaging and real-time monitoring add roughly $70–150 per shipment. Slot management systems implemented in 2024 reduced on-site waste by an estimated 10–20%, improving yield. Returns and expiries remain material, commonly eroding 5–8% of product value and pressuring gross margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, marketing, and medical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eField teams, targeted education programs, and congress presence drive clinician and hospital awareness while health economics and HEOR dossiers support reimbursement and access decisions; KOL engagement and peer-reviewed publications are ongoing cost centers. CRM platforms and digital marketing tools add recurring subscription and maintenance spend that scale with commercial reach.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField teams \u0026amp; education: awareness\u003c\/li\u003e\n\u003cli\u003eHEOR: access support\u003c\/li\u003e\n\u003cli\u003eKOLs \u0026amp; publications: fixed\/variable spend\u003c\/li\u003e\n\u003cli\u003eCRM\/digital: recurring costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSubmission preparation and audits demand dedicated regulatory teams and external consultants, driving recurring personnel and contractor costs; pharmacovigilance systems operate continuously for real-time signal detection and case management; quality systems and CAPAs require ongoing validation, training and documentation budgets; legal and IP protection incur patent maintenance, freedom-to-operate analyses and potential litigation expenses.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDedicated regulatory staff and consultants\u003c\/li\u003e\n\u003cli\u003e24\/7 pharmacovigilance infrastructure\u003c\/li\u003e\n\u003cli\u003eQuality systems, CAPA maintenance\u003c\/li\u003e\n\u003cli\u003eLegal, patent and IP defense costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadiopharma costs: \u003cstrong\u003e\u0026gt;70%\u003c\/strong\u003e R\u0026amp;D, trials $1-100M, cold-chain +20-35%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D (discovery→clinical) \u0026gt;70% of spend; 2024 averages: preclinical $1–5M, Phase I $1–4M, Phase II $7–20M, Phase III $20–100M. Isotope\/precursor volatility (Tc‑99m, Ga‑68) raised inputs; cold‑chain freight +20–35% and $70–150\/shipment; product returns 5–8%. Commercial, regulatory, QA\/PV and IP are recurring fixed\/variable overheads, regulatory\/PV ~$1–10M\/yr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost Item\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial costs\u003c\/td\u003e\n\u003ctd\u003ePre $1–5M; PhI $1–4M; PhII $7–20M; PhIII $20–100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreight\/cold‑chain\u003c\/td\u003e\n\u003ctd\u003e+20–35%; $70–150\/shipment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReturns\/expiries\u003c\/td\u003e\n\u003ctd\u003e5–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/PV\u003c\/td\u003e\n\u003ctd\u003e$1–10M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct sales (diagnostic agents)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecurring revenue from PET\/SPECT tracers is driven by per-scan use; the U.S. performs about 2 million PET scans annually, creating steady demand for radiopharmaceutical doses. Hospital systems and imaging centers drive volume, with large networks purchasing regularly and stocking tracers. Pricing in 2024 reflects clinical value and supply complexity, with typical U.S. per-dose prices commonly ranging from $1,000 to $2,500. Contract terms vary by GPO and individual account.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic and theranostic sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue derives from targeted radiotherapeutics and paired theranostic offerings, leveraging FDA-approved agents such as PYLARIFY (piflufolastat F 18, approved 2021) and Pluvicto (lutetium-177 vipivotide tetraxetan, approved 2022) to command premium pricing tied to demonstrated outcomes. Companion imaging drives utilization and referral capture, enhancing therapy uptake. Expanding indications for PSMA and NETs broaden the addressable market and lifetime patient value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOut-licensing Lantheus IP and platforms generates ongoing royalties, with industry royalty rates commonly in the 5–15% range providing steady, recurring cash flow. Partners commercialize products in select geographies or indications, de-risking market entry and accelerating uptake. Development and regulatory milestones—often structured as one-time payments ranging from low‑single to triple‑digit millions industrywide—add upside, while cross‑licensing deals reduce development risk and lower R\u0026amp;D spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServices and technical support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eServices and technical support generate recurring fees through training, validation, and implementation services that accelerate site adoption and billing realization; peers increasingly price site enablement at premium rates. Data services and decision-support tools create high-margin, scalable revenue and lift per-customer lifetime value. Customized protocols and ongoing service contracts deepen relationships and convert one-time buyers into multi-year revenue streams aligned with 2024 industry trends (global medical imaging market ~47 billion USD in 2024).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTraining, validation, implementation — fee-based site enablement\u003c\/li\u003e\n\u003cli\u003eData services \u0026amp; decision-support — scalable, high-margin\u003c\/li\u003e\n\u003cli\u003eCustomized protocols — billable professional services\u003c\/li\u003e\n\u003cli\u003eService contracts — increase recurring revenue and retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative funding and milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborative co-development deals deliver upfront payments and share R\u0026amp;D costs, de-risking Lantheus pipeline and improving cash flow. Regulatory and sales milestones generate near-term cash infusions as assets hit clinical or commercial triggers in 2024. Sponsored research offsets trial costs while joint commercialization provides profit-share revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-development: upfronts and R\u0026amp;D cost sharing\u003c\/li\u003e\n\u003cli\u003eMilestones: regulatory and sales cash infusions (2024)\u003c\/li\u003e\n\u003cli\u003eSponsored research: trial cost offsets\u003c\/li\u003e\n\u003cli\u003eJoint commercialization: profit share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecurring PET\/SPECT doses and theranostics drive premium, high-margin recurring revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecurring PET\/SPECT doses (US ~2M scans\/year) drive steady per-dose revenue ($1,000–$2,500 in 2024). Theranostics (PYLARIFY, Pluvicto) command premium pricing and expand lifetime value as indications grow. Royalties (5–15%), milestones (low‑single to triple‑digit $M) and services\/data add high-margin recurring cash.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 KPI\u003c\/th\u003e\n\u003cth\u003ePrice\/Margin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTracers\u003c\/td\u003e\n\u003ctd\u003eUS ~2M PET scans\u003c\/td\u003e\n\u003ctd\u003e$1k–$2.5k\/dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTheranostics\u003c\/td\u003e\n\u003ctd\u003eExpanding indications\u003c\/td\u003e\n\u003ctd\u003ePremium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e5–15%\u003c\/td\u003e\n\u003ctd\u003eHigh-margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098215190876,"sku":"lantheus-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/lantheus-business-model-canvas.png?v=1781799351","url":"https:\/\/pestel-analysis.com\/products\/lantheus-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}